MaxCyte, Inc. (MXCT) Insider Trading Activity

NASDAQ$1.47
Market Cap
$156.81M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
190 of 827
Rank in Industry
22 of 107

MXCT Insider Trading Activity

MXCT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$480,175
5
36
Sells
$106,966
9
64

Related Transactions

Erck Stanley Cdirector
1
$137,220
0
$0
$137,220
DOUGLAS RICHARDdirector
1
$111,040
0
$0
$111,040
Masoud MaherPresident and CEO
1
$102,915
0
$0
$102,915
Brooke William Wdirector
1
$64,500
0
$0
$64,500
Swirsky Douglas JCHIEF FINANCIAL OFFICER
1
$64,500
1
$22,061
$42,439
Soleymannezhad AliChief Commercial Officer
0
$0
1
$3,850
$-3,850
Sandoval David I.GENERAL COUNSEL
0
$0
2
$21,394
$-21,394
Hemrajani Rekhadirector
0
$0
1
$22,378
$-22,378
Johnston John Josephdirector
0
$0
4
$37,284
$-37,284

About MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Insider Activity of MaxCyte, Inc.

Over the last 12 months, insiders at MaxCyte, Inc. have bought $480,175 and sold $106,966 worth of MaxCyte, Inc. stock.

On average, over the past 5 years, insiders at MaxCyte, Inc. have bought $12.14M and sold $12.28M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Erck Stanley C (director) — $137,220. DOUGLAS RICHARD (director) — $111,040. Masoud Maher (President and CEO) — $102,915.

The last purchase of 50,000 shares for transaction amount of $64,500 was made by Brooke William W (director) on 2025‑08‑13.

List of Insider Buy and Sell Transactions, MaxCyte, Inc.

2025-08-13PurchaseErck Stanley Cdirector
100,000
0.0933%
$1.37
$137,220
+12.32%
2025-08-13PurchaseDOUGLAS RICHARDdirector
80,000
0.0755%
$1.39
$111,040
+12.32%
2025-08-13PurchaseMasoud MaherPresident and CEO
75,000
0.07%
$1.37
$102,915
+12.32%
2025-08-13PurchaseSwirsky Douglas JCHIEF FINANCIAL OFFICER
50,000
0.0438%
$1.29
$64,500
+12.32%
2025-08-13PurchaseBrooke William Wdirector
50,000
0.0438%
$1.29
$64,500
+12.32%
2025-06-25SaleHemrajani Rekhadirector
10,684
0.0094%
$2.09
$22,378
-27.80%
2025-03-18SaleSwirsky Douglas JCHIEF FINANCIAL OFFICER
6,939
0.0066%
$3.18
$22,061
-35.11%
2025-03-18SaleSandoval David I.GENERAL COUNSEL
353
0.0003%
$3.18
$1,122
-35.11%
2025-03-18SaleSoleymannezhad AliChief Commercial Officer
1,211
0.0011%
$3.18
$3,850
-35.11%
2025-01-27SaleJohnston John Josephdirector
3,000
0.0029%
$4.64
$13,935
-51.55%
2025-01-13SaleSandoval David I.GENERAL COUNSEL
4,466
0.0039%
$4.54
$20,272
-55.19%
2024-12-26SaleJohnston John Josephdirector
3,000
0.0028%
$4.01
$12,021
-45.21%
2024-12-09SaleJohnston John Josephdirector
2,495
0.0021%
$3.79
$9,459
-46.16%
2024-12-06SaleJohnston John Josephdirector
505
0.0005%
$3.70
$1,869
-37.50%
2024-11-01SaleErck Stanley Cdirector
47,689
0.0448%
$3.72
$177,403
-35.54%
2024-10-28SaleJohnston John Josephdirector
3,000
0.0028%
$3.72
$11,166
-29.64%
2024-10-02SaleErck Stanley Cdirector
21,607
0.0196%
$3.71
$80,162
-24.73%
2024-10-01SaleErck Stanley Cdirector
26,082
0.0241%
$3.78
$98,590
-23.78%
2024-09-26SaleJohnston John Josephdirector
3,000
0.0028%
$3.82
$11,460
-26.48%
2024-09-04SaleErck Stanley Cdirector
29,767
0.0288%
$3.97
$118,175
-13.85%
Total: 101
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Erck Stanley Cdirector
398328
0.3734%
$585,542.1615
DOUGLAS RICHARDdirector
230577
0.2162%
$338,948.1930
<0.0001%
Masoud MaherPresident and CEO
175000
0.1641%
$257,250.0033
<0.0001%
Swirsky Douglas JCHIEF FINANCIAL OFFICER
161811
0.1517%
$237,862.1711
Brooke William Wdirector
150879
0.1414%
$221,792.1310
Johnston John Josephdirector
141950
0.1331%
$208,666.50018
Sandoval David I.GENERAL COUNSEL
64219
0.0602%
$94,401.9302
Soleymannezhad AliChief Commercial Officer
59439
0.0557%
$87,375.3301
Hemrajani Rekhadirector
39893
0.0374%
$58,642.7101
Casdin Elidirector
10000000
9.3744%
$14.7M02
Casdin Partners Master Fund, L.P.10 percent owner
10000000
9.3744%
$14.7M12
<0.0001%
Doerfler DouglasPresident and CEO
333197
0.3124%
$489,799.59023
Holtz RonSVP and CAO
125251
0.1174%
$184,118.9703
Ross Thomas M.EVP, GLOBAL SALES
25000
0.0234%
$36,750.00027
Murphy Amanda LouiseChief Financial Officer
0
0%
$003
*Gray background shows insiders who have made transactions during last year

MXCT Institutional Investors: Active Positions

Increased Positions52+35.14%11M+14.96%
Decreased Positions63-42.57%11M-15.12%
New Positions19New6MNew
Sold Out Positions22Sold Out5MSold Out
Total Postitions137-7.43%74M-0.16%

MXCT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$17,572.009.33%9.98M-218,330-2.14%2025-09-30
Cadian Capital Management, Lp$14,481.007.69%8.23M-686,873-7.71%2025-09-30
Mirabella Financial Services Llp$14,432.007.66%8.2M+2M+24.24%2025-09-30
Morgan Stanley$11,785.006.26%6.7M-329,584-4.69%2025-09-30
Vanguard Group Inc$9,835.005.22%5.59M-13,587-0.24%2025-09-30
Vitruvian Partners Llp$8,876.004.71%5.04M00%2025-09-30
Mudita Advisors Llp$5,932.003.15%3.37M00%2025-09-30
River Global Investors Llp$5,726.003.04%3.25M+1M+57.73%2024-12-31
Axa Investment Managers S.A.$4,881.002.59%2.77M+3MNew2025-09-30
Geode Capital Management, Llc$4,505.002.39%2.56M+79,144+3.19%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.